Last reviewed · How we verify
Etocox (ETORICOXIB)
Etoricoxib, marketed as Etocox, is a nonsteroidal anti-inflammatory drug (NSAID) currently on the market, positioned in the selective COX-2 inhibitor class. Its key strength lies in its mechanism of action, which effectively blocks prostaglandin E2 to reduce pain and inflammation, offering a targeted approach to treatment. The primary risk is the upcoming key patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | ETORICOXIB |
|---|---|
| Drug class | etoricoxib |
| Target | Mitogen-activated protein kinase 14, Prostaglandin E2 receptor EP2 subtype, Prostaglandin G/H synthase 1 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 2002 |
Approved indications
Common side effects
Key clinical trials
- Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination (PHASE1)
- Assessing the Benefits of Dry Needling for Low Back Pain When Combined With Regular Treatment (PHASE4)
- Etoricoxib in Patients With Parkinsonian Disease (PHASE2)
- Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm (PHASE3)
- Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis (PHASE3)
- Multimodal Imaging and Biospecimen Collection for Low Back Pain (LBPB)
- Venous Cannulation Pain to Guide Choice of Anesthetic Method (NA)
- Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etocox CI brief — competitive landscape report
- Etocox updates RSS · CI watch RSS